SOUTH SAN FRANCISCO, California, July 16 (TNSjou) -- Genentech, a member of the Roche Group, issued the following news release on July 14, 2026:

* * *

FDA Grants Priority Review to Genentech's Gazyva for Adults With Primary Membranous Nephropathy

* Priority review decision is based on Phase III MAJESTY results, where Gazyva achieved significantly higher complete remission rates at two years compared to tacrolimus

* If approved, Gazyva will . . .

Click here for more information about our products